120
Participants
Start Date
July 14, 2025
Primary Completion Date
January 15, 2027
Study Completion Date
July 15, 2027
Utidelone
Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle.
Utidelone in combination with capecitabine
UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Utidelone in combination with capecitabine
Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Utidelone in combination with capecitabine
Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
RECRUITING
Community Clinical Trials, Kingwood
NOT_YET_RECRUITING
East Carolina University, Greenville
NOT_YET_RECRUITING
Augusta University, Augusta
RECRUITING
Biosresearch Partner, Hialeah
RECRUITING
D&H Cancer Research Center, Margate
RECRUITING
Profound Research LLC, Farmington Hills
NOT_YET_RECRUITING
Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
NOT_YET_RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Tranquil Clinical Research, Webster
RECRUITING
University Of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
RECRUITING
Comprehensive Cancer Centers of Nevada, Las Vegas
RECRUITING
Cancer & Blood Research Center, LLC, Los Alamitos
NOT_YET_RECRUITING
City of Hope--Duarte, Duarte
RECRUITING
Scripps Health, San Diego
RECRUITING
FOMAT Medical Research (Network), Oxnard
NOT_YET_RECRUITING
Stony Brook Cancer Center, Stony Brook
Lead Sponsor
Biostar Pharma, Inc.
INDUSTRY